Peptides DB

Research-centric peptide and protocol reference hub

comparison

16 articles in this category.

comparisonJul 16, 2026

Ozempic vs Wegovy vs Mounjaro: GLP-1 Drugs Compared

Ozempic vs Wegovy vs Mounjaro explained: four brands, two molecules. Compare approved uses, mechanism, side effects, eligibility, and insurance coverage.

7 min read
comparisonJul 16, 2026

Liraglutide vs Semaglutide: How They Compare

Liraglutide vs semaglutide compared: mechanism, brands, dosing frequency, formulations, side effects, and coverage. Both are FDA-approved and prescription-only.

7 min read
comparisonJul 16, 2026

Mounjaro vs Ozempic Side Effects Compared

Mounjaro vs Ozempic side effects compared: shared GI symptoms, boxed warnings, who is at higher risk, and how clinicians manage tolerability.

7 min read
comparisonJul 16, 2026

Rybelsus vs Ozempic: Oral vs Injectable Semaglutide

Rybelsus vs Ozempic: same semaglutide, different form. Compare the daily oral tablet and the weekly injection on use, side effects, and coverage.

7 min read
comparisonJul 16, 2026

Trulicity vs Ozempic: Comparing Two GLP-1 Drugs

Trulicity vs Ozempic compared: dulaglutide and semaglutide are both once-weekly GLP-1 drugs for type 2 diabetes. Mechanism, side effects, and coverage.

7 min read
comparisonJul 16, 2026

Zepbound vs Mounjaro: Same Drug, Two Brands

Zepbound vs Mounjaro: both are tirzepatide from Eli Lilly. The difference is the FDA-approved use — weight management vs type 2 diabetes.

6 min read
comparisonJul 15, 2026

Zepbound vs Wegovy: How They Compare for Weight Loss

Zepbound vs Wegovy: Zepbound is tirzepatide, Wegovy is semaglutide. Both are FDA-approved for weight management. Here's how the two compare.

6 min read
comparisonJun 18, 2026

AOD-9604 vs Semaglutide: Why They're Not Comparable

AOD-9604 and Semaglutide both appear in 'fat-loss peptide' conversations but they're not comparable interventions. Semaglutide is FDA-approved with ~15% trial weight loss; AOD-9604 has weak human evidence and minimal trial effect.

4 min read
comparisonJun 18, 2026

BPC-157 vs Semaglutide: Healing Peptide vs Weight-Loss Drug

BPC-157 and Semaglutide solve completely different problems — healing vs weight loss. Here's why the comparison comes up, what each actually does, and when (if ever) they're used together.

4 min read
comparisonJun 18, 2026

Mounjaro vs Ozempic: Tirzepatide vs Semaglutide, Brand by Brand

Mounjaro is Tirzepatide; Ozempic is Semaglutide. Different molecules, different mechanisms, different effect sizes. Here's the brand-level comparison plus insurance and pen-format differences.

4 min read
comparisonJun 18, 2026

Ozempic vs Wegovy: Same Drug, Different Indications

Ozempic and Wegovy are both Semaglutide. The differences are dose ceiling, FDA-approved indication, packaging, and insurance coverage — not the molecule. Here's how to think about them.

4 min read
comparisonJun 14, 2026

BPC-157 vs TB-500: How They Compare for Healing

BPC-157 and TB-500 are the two most-discussed healing peptides. Here's how they actually compare on mechanism, evidence, dosing, side effects, and which one (or both) makes sense for which goal.

7 min read
comparisonJun 14, 2026

CJC-1295 / Ipamorelin vs Sermorelin: GH Secretagogue Choices

CJC-1295 + Ipamorelin stack vs Sermorelin alone — mechanism differences, GH pulse magnitude, side-effect profiles, and which to choose for which goal.

6 min read
comparisonJun 14, 2026

Ipamorelin vs CJC-1295: Mechanism, Effects, and Why They're Stacked

Ipamorelin and CJC-1295 work on different receptors and are commonly combined. Here's how they compare individually and why the stack produces a larger GH pulse than either alone.

6 min read
comparisonJun 14, 2026

Semaglutide vs Tirzepatide: Mechanism, Trial Data, Which to Choose

Semaglutide vs Tirzepatide — head-to-head on mechanism (GLP-1 vs GIP+GLP-1), Phase 3 weight loss (~15% vs ~21%), side effects, cardiovascular evidence, and how to choose.

6 min read
comparisonJun 14, 2026

Tirzepatide vs Retatrutide: Dual vs Triple Receptor Agonism

Tirzepatide is FDA-approved GIP+GLP-1 dual agonism (~21% weight loss). Retatrutide is GLP-1+GIP+glucagon triple agonism in Phase 3 (~24% Phase 2). Here's how they compare.

5 min read